Harrow Inc

HROW remains in a Stage 2 advance with accelerating demand evident in an active Parabola pattern. Medium-term bias stays bullish supported by rising higher-highs and higher-lows along with positive moving averages. Price is extended above key EMAs in an extreme overbought context, suggesting pullbacks into rising EMA support near the breakout zone may offer optimal entry. Execution is deferred, stalking for a disciplined pullback to participate in the ongoing uptrend.

• ↑Q1 revenues reached $44.2M with full-year guidance of $350M–365M
• ↑New VIVI scripts up 25% sequentially, underpinning dry eye growth
• ↓Q1 adjusted EBITDA at –$12.7M underscores early-stage loss profile